EyePoint: Topline Data in Phase 2 AMD Trial

 

• Subgroup analyses underscore favorable clinical profile and durability of EYP-1901
• Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results showing all primary and secondary endpoints were met
• Results presented today at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

https://www.biospace.com/article/releases/eyepoint-pharmaceuticals-announces-two-presentations-of-topline-data-with-additional-subgroup-analyses-from-the-phase-2-davio-2-clinical-trial-of-eyp-1901-for-the-treatment-of-wet-age-related-macular-degeneration/